Page 52 - Read Online

Imaging 2007;34:1617-26. 60. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V,
49. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger Kulkarni H, Haugvik SP, Hommann M, Baum RP. Molecular imaging
M, Perren A. Correlation of immunohistopathological expression of with 68Ga-SSTR PET/CT and correlation to immunohistochemistry
somatostatin receptor 2 with standardised uptake values in Ga- of somatostatin receptors in neuroendocrine tumours. Eur J Nucl
68
DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2008;36:48-52. Med Mol Imaging 2011;38:1659-68.
50. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke 61. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical
HR. Preclinical evaluation of new and highly potent analogues of management of advanced neuroendocrine tumors. Endocr Rev
octreotide for predictive imaging and targeted radiotherapy. Clin 2004;25:458-511.
Cancer Res 2005;11:1136-45. 62. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-
51. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch
Mäcke HR. Affinity profiles for human somatostatin receptor subtypes D, Hammel P, Wiedenmann B, Van Cutsem P, Patyna S, Lu DR,
SST1-SST5 of somatostatin radiotracers selected for scintigraphic Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for
and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82. the treatment of pancreatic neuroendocrine tumors. N Engl J Med
52. Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha 2011;364:501-13.
MM, Lata S, Kumar R, Malhotra A, Bal C. Dual tracer functional 63. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E,
imaging of gastroenteropancreatic neuroendocrine tumors using Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti
18
68 Ga-DOTA-NOC PET-CT and F-FDG PET-CT: competitive or P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K.
complimentary? Clin Nucl Med 2014;39:e27-34. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl
53. Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, J Med 2011;364:514-23.
Gildehaus FJ, Bartenstein P, Angele MK, Haug AR. Impact of 64. Hofman MS, Hicks RJ. Changing paradigms with molecular
68 Ga-DOTATATE PET/CT on the surgical management of primary imaging of neuroendocrine tumors. Discov Med 2012;14:71-81.
neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol 65. Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan
2014;22:164-71. GD, Sharif R, MacKenzie S, Kosari K, Barakat O, Naqvi S, Seng
54. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller JE, Anthony L. Long-term survival, toxicity profile, and role of F-18
T, Anlauf M, Wiedenmann B, Salazar R. ENETS consensus FDG PET/CT scan in patients with progressive neuroendocrine
guidelines for the management of patients with liver and other tumors following peptide receptor radionuclide therapy with high
distant metastases from neuroendocrine neoplasms of foregut, activity In-111 Pentetreotide. Theranostics 2012;2:472-80.
midgut, hindgut, and unknown primary. Neuroendocrinology 66. Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P,
2012;95:157-76. Zannino D, Hicks RJ. Favourable outcomes of 177Lu-octreotate
55. Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti peptide receptor chemoradionuclide therapy in patients with
S, Scarpi E, Matteucci F, Gilardi L, Paganelli G. Role of 18FDG FDG-avid neuroendocrine tumors. Eur J Nucl Med Mol Imaging
PET/CT in patients treated with 177Lu-DOTATATE for advanced 2014;42:176-85.
differentiated neuroendocrine tumours. Eur J Nucl Med Mol 67. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C,
Imaging 2013;40:881-8. Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M. 68Ga-
56. Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, DOTATATE PET/CT for the early prediction of response to
Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin somatostatin receptor-mediated radionuclide therapy in patients
E. High prognostic value of 18F-FDG PET for metastatic with well-differentiated neuroendocrine tumors. J Nucl Med
gastroenteropancreatic neuroendocrine tumors: a long-term 2010;51:1349-56.
evaluation. J Nucl Med 2014;55:1786-90. 68. Wang L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, Zhang H, Wang
57. Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, Zhang H. Somatostatin
K. 68Gallium- and 90Yttrium-/177Lutetium: ‘theranostic twins’ for receptor-based molecular imaging and therapy for neuroendocrine
diagnosis and treatment of NETs. Ann Nucl Med 2015;29:1-7. tumors, somatostatin receptor-based molecular imaging and therapy
58. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of for neuroendocrine tumors. BioMed Res Int 2013;2013:e102819.
advanced neuroendocrine tumours with radiolabelled somatostatin 69. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D,
analogues. Endocr Relat Cancer 2005;12:683-99. Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ. 68Ga-DOTA-
59. Oh S, Prasad V, Lee DS, Baum RP, Oh S, Prasad V, Lee DS, Baum Tyr3-Octreotide PET for assessing response to somatostatin-receptor-
RP. Effect of peptide receptor radionuclide therapy on somatostatin mediated radionuclide therapy. J Nucl Med 2009;50:1427-34.
receptor status and glucose metabolism in neuroendocrine tumors: 70. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to
intraindividual comparison of Ga-68 DOTANOC PET/CT and PERCIST: evolving considerations for PET response criteria in
F-18 FDG PET/CT, effect of peptide receptor radionuclide solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
therapy on somatostatin receptor status and glucose metabolism 71. Ziai D, Wagner T, El Badaoui A, Hitzel A, Woillard JB, Melloni
in neuroendocrine tumors: intraindividual comparison of Ga-68 B, Monteil J. Therapy response evaluation with FDG-PET/CT in
DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging small cell lung cancer: a prognostic and comparison study of the
2011;2011:e524130. PERCIST and EORTC criteria. Cancer Imaging 2013;13:73-80.

328
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦